Alvotech/Teva bring new partner to expand access for Humira biosimilar in U.S.
https://seekingalpha.com/news/4091382-alvotech-signs-u-s-agreement-to-expand-access-for-newly-approved-high-concentration?source=feed_sector_healthcare
Apr 19, 2024 - Alvotech (ALVO) in agreement with Teva Pharmaceuticals (TEVA), signed a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryv in US market.
0
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
https://www.zacks.com/commentary/2257822/3-generic-drug-stocks-to-watch-amid-challenging-market-prospects?cid=CS-ZC-FT-industry_outlook-2257822
Apr 18, 2024 - The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.
0
Teva confirms efficacy in late-stage trial of its migraine treatment for adult Chinese patients
https://seekingalpha.com/news/4088897-teva-confirms-efficacy-in-late-stage-trial-of-its-migraine-treatment-for-adult-chinese-patients?source=feed_tag_israel
Apr 11, 2024 - Late-stage study confirms efficacy and safety of Teva Pharmaceutical's AJOVY in preventing migraines in adult Chinese patients.
0
Teva and mAbxience sign global licensing agreement for oncology biosimilar candidate
https://seekingalpha.com/news/4087243-teva-and-mabxience-sign-global-licensing-agreement-for-oncology-biosimilar-candidate?source=feed_tag_israel
Apr 04, 2024 - Teva Pharmaceuticals and mAbxience have signed a strategic licensing agreement to develop a biosimilar treatment for multiple oncology indications,...
0
Teva and Viatris revives chance to dispute J&J's schizophrenia drug patent
https://seekingalpha.com/news/4085739-teva-and-viatris-revives-chance-to-dispute-jjs-schizophrenia-drug-patent?source=feed_sector_healthcare
Apr 01, 2024 - Teva Pharmaceuticals and Viatris have been given a new opportunity to challenge the patent for Johnson and Johnson's schizophrenia drug in a U.S.
0
Teva stock trades in the green for seventh straight session
https://seekingalpha.com/news/4084589-teva-on-track-for-seventh-straight-day-of-gains?source=feed_tag_israel
Mar 27, 2024 - Teva Pharmaceutical (TEVA) shares are on the rise, gaining for the 7th consecutive day.
0
Teva Pharmaceutical Industries: Potential Outweighs Concerns
https://seekingalpha.com/article/4680308-teva-pharmaceutical-industries-potential-outweighs-concerns?source=feed_tag_israel
Mar 25, 2024 - Teva Pharmaceutical is deeply undervalued, trading at a 77% discount per my calculations. The new CEO's turnaround plan looks promising. Find out why TEVA stock is a Buy.
0
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
https://www.zacks.com/stock/news/2245567/will-corcept-cort-bank-on-korlym-in-2024-amid-stiff-rivalry?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245567
Mar 25, 2024 - Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
0
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405
Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
0
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
https://www.zacks.com/stock/news/2243035/astrazeneca-azn-follows-boehringer-to-cap-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243035
Mar 19, 2024 - AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
0
Page 1>